Eloxx Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ELOX Nasdaq 8731 https://www.eloxxpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement - Jun 6th, 2023 12:30 pm
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer - Jun 1st, 2023 1:10 pm
Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome - May 24th, 2023 6:01 pm
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study - May 24th, 2023 12:00 pm
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update - May 15th, 2023 8:30 pm
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013 - May 2nd, 2023 12:00 pm
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update - Apr 3rd, 2023 12:00 pm
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013 - Mar 28th, 2023 8:45 pm
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference - Mar 6th, 2023 9:10 pm
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed - Feb 27th, 2023 9:05 pm
Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate - Feb 24th, 2023 1:01 pm
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome - Jan 25th, 2023 1:00 pm
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective - Dec 1st, 2022 1:45 pm
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update - Nov 10th, 2022 10:15 pm
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome - Nov 1st, 2022 8:30 pm
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal - Sep 16th, 2022 3:42 pm
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients - Sep 14th, 2022 8:05 pm
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update - Aug 15th, 2022 12:00 pm
Eloxx Pharmaceuticals Announces Changes to Board of Directors - Jul 5th, 2022 12:00 pm